肥満患者および肥満患者における心不全の分類のためのナトリウレチンペプチドカットポイント
Mandana Chitsazan1,2,3, Juhi K Parekh2,3, Leah B Kosyakovsky1,2,3
1Harvard Medical School, Boston, MA (M.C., L.B.K., J.L.J., J.E.H.).
Circulation. Heart failure
|August 20, 2025
まとめ
単一のナトリウレチンペプチド (NP) 切断点は,肥満における心不全 (HF) リスクを誤って分類する可能性があります. 肥満に対するNP値の調整は,心不全前期 (ステージB HF) の患者のリスク評価を改善する可能性があります.
科学分野:
- 心臓病科
- バイオマーカー
- 肥満 医学
背景:
- 2022年のAHA/ACC/HFSAガイドラインでは,B段階の心不全 (HF) を定義し,高リスクの個人を特定するために,上昇したナトリウレチンペプチド (NP) を使用しています.
- 肥満はNPレベルに影響し,この新しいHF定義の正確さに潜在的に影響を及ぼします.
研究 の 目的:
- 肥満が正常体重の個人に比べて不均衡に B HF に分類されるかどうかを調査する.
- 肥満がNPレベルに与える影響と将来のHFリスクとの関連を評価する.
主な方法:
- 5つのコミュニティコホートから32,735人の参加者を分析した.
- ステージBのHF再分類の比較は,2022対2013のガイドラインを使用して,肥満のクラスによって分層化されています.
- 肥満クラスにおけるNP-HFリスク関連を調べるためにコックスの比例リスクモデルを使用した.
主要な成果:
- 単一のNP切断点では,正常体重の個体 (62%) と比較して,肥満の個体 (42-47%) がB段階のHFに昇格しました.
- 高いNPとボディマス指数は,独立してHFのリスク増加と関連していた (P< 0. 0001).
- HFリスクを予測するための最適NT-proBNPカットポイントは,肥満の個体 (80 pg/ mL) と正常体重の個体 (109 pg/ mL) の間で低かった.
結論:
- 均一なNP切断点は,肥満の個体におけるHFリスクの低分類につながる可能性があります.
- 肥満状態に基づくNPカットポイントの調整は,ステージBのHF識別とHFリスクの階層化の精度を高めることができます.
関連する概念動画
01:29Heart Failure II: Pathophysiology
33
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
33
01:30Heart Failure IV: Classification and Diagnostic Evaluation
31
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
31
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
213
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
213
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K